

Marjorie G Zauderer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5319752/publications.pdf>

Version: 2024-02-01

49
papers

3,501
citations

201385

27
h-index

205818

48
g-index

51
all docs

51
docs citations

51
times ranked

4449
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing a cancer-specific geriatric assessment. <i>Cancer</i> , 2005, 104, 1998-2005.	2.0	541
2	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	7.7	422
3	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.	157.7	306
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
5	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	7.7	222
6	Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768.	0.8	154
7	Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1278-1283.	0.4	142
8	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	1.9	119
9	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.	3.2	103
10	Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 84, 271-274.	0.9	101
11	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
12	Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1430-1433.	0.5	81
13	New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment. <i>Clinical Cancer Research</i> , 2012, 18, 4485-4490.	3.2	77
14	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 303-311.	2.9	65
15	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.	0.4	55
16	Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 249-255.	0.5	53
17	Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 993-1000.	0.5	53
18	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767.	5.1	49

#	ARTICLE	IF	CITATIONS
19	Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 205-210.	1.1	48
20	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	3.2	48
21	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 151-156.	1.1	47
22	Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. <i>Lung Cancer</i> , 2014, 86, 237-240.	0.9	47
23	The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2011, 12, 163-172.	1.3	37
24	Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. <i>Genome Medicine</i> , 2019, 11, 18.	3.6	36
25	Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study. <i>International Journal of Cancer</i> , 2017, 140, 1976-1984.	2.3	35
26	A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1272-1277.	0.5	33
27	Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses $\text{NF-}\kappa\text{B}$ Loss-Driven Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1693-1704.	1.9	31
28	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. <i>Oncotarget</i> , 2017, 8, 77872-77882.	0.8	31
29	Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. <i>Lancet Oncology</i> , 2016, 17, e43-e44.	5.1	28
30	Molecular Characterization of Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2022, 17, 455-460.	0.5	24
31	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576.	5.9	23
32	Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 42-47.	2.3	22
33	Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69.	0.4	19
34	Toxicity of initial chemotherapy in older patients with lung cancers. <i>Journal of Geriatric Oncology</i> , 2013, 4, 64-70.	0.5	18
35	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063.	1.1	17
36	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.	0.9	15

#	ARTICLE	IF	CITATIONS
37	A new standard for malignant pleural mesothelioma. <i>Lancet, The</i> , 2016, 387, 1352-1354.	6.3	14
38	Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. <i>Drugs and Aging</i> , 2005, 22, 709-715.	1.3	13
39	Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry. <i>American Journal of Industrial Medicine</i> , 2020, 63, 105-114.	1.0	12
40	Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015, 2015, 170-172.	0.2	11
41	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.	1.1	10
42	Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 487-90.	0.6	9
43	Nivo-lution in Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5438-5440.	3.2	7
44	Leptomeningeal Metastases from Small Cell Lung Cancer Responsive to Temozolomide Therapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1716-1717.	0.5	5
45	The therapeutic implications of the genomic analysis of malignant pleural mesothelioma. <i>Nature Communications</i> , 2021, 12, 1819.	5.8	3
46	Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy. <i>Journal of Immunotherapy</i> , 2021, Publish Ahead of Print, .	1.2	3
47	Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. <i>Oncologist</i> , 2022, 27, 610-614.	1.9	2
48	Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. <i>Current Cancer Research</i> , 2017, , 313-345.	0.2	1
49	Novel and Targeted Therapies. , 2012, , 95-101.		0